CADL

Candel Therapeutics has experienced several stock events in the past six months. Positive clinical trial data from the Phase 3 trial of CAN-2409 in localized prostate cancer and extended survival data from the Phase 2a trial of CAN-2409 in advanced non-small cell lung cancer have contributed to analyst optimism and stock rallies. The company received FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for prostate cancer and Fast Track Designation for CAN-2409 and CAN-3110, as well as Orphan Drug Designation for CAN-3110. Candel Therapeutics announced a commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec in localized prostate cancer. The company announced a proposed underwritten public offering of $100 million of its common stock to fund launch readiness, development costs, and general corporate purposes. The stock has seen increased analyst coverage, with firms initiating coverage with positive ratings and price targets. The share price increased significantly over the past year, outperforming the US Biotechs industry and the US Market, reaching a new 52-week high.